Sagimet Biosciences Inc.
SGMTHealthcare|Biotechnology|US
$9.85
+0.73 (+8.00%)
DCF Value
$1.05
Tangible Book / Share
$4.82
Cash / Share
$4.52
Clinical Trials (13)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07863193 Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA) | Acne Vulgaris | P3 | Recruiting | 800 | RCT, Double-blind | Denifanstat |
| NCT03808558 Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas | KRAS Gene Mutation | P2 | Active | 18 | Open-label | TVB-2640 |
| NCT06989840 Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne | Acne | P1 | Recruiting | 152 | RCT, Double-blind | TVB-3567, Placebo |
| NCT05743621 Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer | Prostatic Neoplasms, Castration-Resistant | P1 | Active | 8 | Open-label | TVB-2640, Enzalutamide |
| NCT06594523 A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis | MASH, NASH | P3 | Withdrawn | — | RCT, Double-blind | Denifanstat, Placebo |
| NCT06692283 A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH | MASLD, MASH | P3 | Withdrawn | — | RCT, Double-blind | denifanstat, Placebo |
| NCT04906421 Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH) | Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease | P2 | Completed | 168 | RCT, Double-blind | TVB-2640 |
| NCT03938246 Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH) | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) | P2 | Completed | 142 | RCT, Single-blind | TVB-2640 25 mg (US), TVB-2640 50 mg (US), Placebo (US), TVB-2640 50 mg (China), Placebo (China), TVB-2640 75 mg (US) |
| NCT02948569 Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome | Metabolic Syndrome | P1P2 | Completed | 12 | Open-label | 3-V Bioscience-2640 |
| NCT02223247 A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors | Solid Malignant Tumor | P1 | Completed | 180 | Open-label | TVB-2640 |
| NCT07216313 A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants | Healthy | P1 | Completed | 40 | Open-label | Denifanstat, Resmetirom |
| NCT05657834 Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male Subjects | Healthy Volunteers | P1 | Completed | 8 | Open-label | [14C]-TVB-2640 |
| NCT05835180 A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function | Non-alcoholic Steatohepatitis, Hepatic Impairment | P1 | Completed | 48 | Open-label | TVB-2640 - 50 mg |